HACKENSACK, N.J.--(BUSINESS WIRE)--ADMA Biologics, Inc. (ADMA), a late-stage biotechnology company focused on the development and commercialization of human plasma and plasma-derived therapeutics, today announced it has appointed Dr. Mond as its Chief Medical and Scientific Officer, where he will be responsible for strategy and advancing the Company’s programs.
